🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Spain / NCT07729969
Recruiting Not applicable

Early Cognitive Interventions in Digital Format for Cancer Survivors

NCT07729969 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-06-08
Last updated
2026-07-28

Condition(s) studied

Cognitive ImpairmentCognitive ChangeCancer

Investigational drug(s) / intervention(s)

Computerized cognitive treatmentVirtual reality cognitive training

Computerized cognitive treatment: Online exercises that target the following functions: attention, processing speed, memory, spatial orientation, interpersonal skills and intelligence. Participants will follow an online cognitive training with the BrainHQ program for 10 weeks. Patients will complete exercises that target attention, executive function, memory and processing speed. They will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week for 10 weeks, a total of 25 hours. Training progresses in an adaptive way, based on the progression of the participant.

Virtual reality cognitive training: A library of 15 cognitive exercises developed in virtual reality to train and monitor specific cognitive functions (memory, attention, task flexibility, information processing, orientation, and problem-solving) and motor control. Participants will follow a virtual reality cognitive training with the Enhance VR program for 10 weeks. Patients will complete exercises that target attention, executive function, memory and processing speed. Participants will be asked to train approximately 30 minutes per Enhance VR session, 4 times per week for 10 weeks, a total of 20 hours. Training progresses in an adaptive way, based on the progression of the participant.

Study summary

The aim of this study is to evaluate the usability and effectiveness of two professionally supervised home-based cognitive training interventions as part of an early rehabilitation protocol for cancer-related cognitive impairment.

Participants will be randomized to one of the two intervention arms (computerized cognitive intervention or virtual reality cognitive intervention) or to the control group. Participants of the intervention groups will be assessed before and after the 10 weeks intervention or at equivalent time points for the control group. Comparisons between experimental and control participants, and between the participants in the two intervention arms, will be carried out to see which intervention is most effective and accepted.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients over 18 years of age diagnosed with cancer (stage I-III) * Subjective complaints of cognitive functioning related to the diagnosis of cancer and/or cancer treatments * Between 1-6 months after completion of chemotherapy treatment * To have Wi-Fi and a computer/tablet * To sign the informed consent form Exclusion Criteria: * Previous history of cancer diagnosis * Anticipated change in cancer treatment/general medical treatment during the intervention period * Previous diagnosis of cognitive impairment * Diagnosis of other neurological or psychiatric diseases * Diagnosis of severe untreated depression * History of episodes of vertigo, epilepsy or seizures * Currently undergoing or having undergone any other type of intervention aimed at improving cognitive functioning (e.g., CRCI workshops) * Severe visual or hearing difficulties that may affect the performance of the intervention exercises * Inability to speak, understand, read, and write Spanish correctly * Failure to sign the informed consent form

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Hospital Universitario Basurto Bilbao Bizkaia Recruiting
Hospital Universitario Galdakao-Usansolo Galdakao Bizkaia Recruiting
Hospital Universitario Donostia San Sebastián Gipuzkoa Recruiting

More Biogipuzkoa Health Research Institute trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07729969 on ClinicalTrials.gov ↗ ← All trials in Spain